| Date | Title | Description | Source |
| 05.03.2024 | Business wind down and take off for listed Swiss startups |
Since its inception in 2012, ObsEva SA (SIX: OBSN) has focused on the development of novel therapie... | startuptic... |
| 09.12.2022 | ObsEva To Increase Issued Share Capital by Creating Addition... | Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland – December ... | einpresswi... |
| 25.11.2022 | Obseva sells rights to its preterm labor treatment for up to... | | startuptic... |
| 22.11.2022 | ObsEva Announces Sale of Ebopiprant License Agreement to XOM... | Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and... | einpresswi... |
| 22.11.2022 | ObsEva Announces Sale of Ebopiprant License Agreement to XOM... | - | globenewsw... |
| 13.09.2022 | ObsEva Announces Progress on Restructuring Initiatives | $7.6 million annual savings expected via reduction-in-force currently underway $6.2 million savings ... | einpresswi... |
| 24.08.2022 | Swiss biotechs in dispute with regulators | | startuptic... |
| 20.06.2022 | Obseva receives its first European Marketing Authorization | | startuptic... |
| 31.01.2022 | ObsEva Announces Corporate Updates | GENEVA, Switzerland - ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing an... | marketscre... |
| 29.01.2022 | ObsEva Announces Corporate Updates | Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland – January 2... | marketscre... |
| 29.01.2022 | ObsEva : Announces Corporate Updates - Form 6-K | ObsEva Announces Corporate Updates
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Excha... | marketscre... |
| 06.01.2022 | ObsEva : Announces Positive Topline Results for Linzagolix 2... | January 6, 2022
-Once daily linzagolix 200mg with ABTmet both co-primary efficacy objectives, demons... | marketscre... |
| 06.01.2022 | ObsEva announces positive results from Phase 3 trials | | startuptic... |
| 30.10.2021 | Press Release : ObsEva Announces Management Change | Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland -- October ... | marketscre... |
| 30.10.2021 | ObsEva Announces Management Change - Form 6-K | ObsEva Announces Management Change
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Excha... | marketscre... |
| 19.10.2021 | ObsEva : Announces Presentation of Clinical Data on Oral GnR... | –Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and final... | marketscre... |
| 19.10.2021 | Press Release : ObsEva Announces Presentation of Clinical Da... | --Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and fina... | marketscre... |
| 14.10.2021 | ObsEva : Announces Relationship with Syneos Health to Commer... | ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
-Linzagolix, an oral Gn... | marketscre... |
| 13.10.2021 | ObsEva : Announces Relationship with Syneos Health to Commer... | ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
-Linzagolix, an oral Gn... | marketscre... |
| 13.10.2021 | Press Release : ObsEva Announces Relationship with Syneos He... | ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
-Linzagolix, an oral Gn... | marketscre... |
| 13.10.2021 | ObsEva Announces Relationship with Syneos Health to Commerci... | ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
-Linzagolix, an oral Gn... | marketscre... |
| 15.09.2021 | ObsEva : Announces Submission of New Drug Application to U.S... | -If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to addr... | marketscre... |
| 15.09.2021 | Press Release : ObsEva Announces Submission of New Drug Appl... | -If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to addr... | marketscre... |
| 11.08.2021 | Timber Pharmaceuticals : 7 Hottest Penny Stocks to Pick Up N... | 7 Hottest Penny Stocks to Pick Up Now
InvestorPlace - Stock Market News, Stock Advice & Trading ... | marketscre... |
| 05.08.2021 | Press Release : ObsEva Announces Second Quarter 2021 Financi... | -Linzagolix (Yselty(R)) for uterine fibroids: US New Drug Application filing planned in Q3:21; Europ... | marketscre... |
| 05.08.2021 | ObsEva receives USD 500 million in upfront and milestone pay... | Under the terms of the agreement, Organon will gain exclusive worldwide rights to develop and commer... | startuptic... |
| 04.08.2021 | Press Release : ObsEva Announces Two Cornerstone Publication... | - A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patients Across Three Random... | marketscre... |
| 04.08.2021 | ObsEva : Announces Two Cornerstone Publications Describing C... | - A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patients Across Three Random... | marketscre... |
| 02.06.2021 | OBSEVA SA
Press Release: ObsEva Announces Oral Presentation... | - Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm l... | marketscre... |
| 02.06.2021 | OBSEVA SA
Press Release : ObsEva Announces Oral Presentatio... | - Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm l... | marketscre... |
| 26.05.2021 | OBSEVA SA
ObsEva : Press Release 25 May 2021 1 | ObsEva Announces Proposed Changes to the Composition of its
Board of Directors
Geneva, Switzerland a... | marketscre... |
| 20.05.2021 | OBSEVA SA
Press Release : ObsEva Announces Final Results fr... | -PRIMROSE 1 76-week results confirm PRIMROSE 2 data showing sustained post-treatment effects and evi... | marketscre... |
| 20.05.2021 | OBSEVA SA
ObsEva : Announces Final Results from the Phase 3... | ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of
Yselty® (linzagolix) for the Tre... | marketscre... |
| 06.05.2021 | OBSEVA SA
Press Release : ObsEva Announces First Quarter 20... | -Yselty(R) for uterine fibroids: US New Drug Application submission planned in Q3:21; European marke... | marketscre... |
| 06.05.2021 | Press Release: ObsEva Announces First Quarter 2021 Financial... | -Yselty(R) for uterine fibroids: US New Drug Application submission planned in Q3:21; European marke... | marketscre... |
| 04.05.2021 | OBSEVA SA
Press Release : ObsEva Announces Enrollment Compl... | - EDELWEISS 3 trial of Yselty(R) expected to report topline data as planned in Q4:21- GENEVA, Switze... | marketscre... |
| 30.04.2021 | OBSEVA SA
Press Release : ObsEva SA presents posters at the... | GENEVA, Switzerland and BOSTON, MA -- April 30, 2021 -- ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a bioph... | marketscre... |
| 27.04.2021 | OBSEVA SA
Press Release : ObsEva Initiates PRIMROSE 3 Bone ... | -Long-term follow-up study to evaluate bone mineral density in women completing at least 20 weeks of... | marketscre... |
| 10.11.2020 | Startups under new leadership | | startuptic... |
| 10.11.2020 | Startups under new leadership | CodeCheck appoints CEO and CFO
With its app for evaluating products, CodeCheck has continued to empo... | startuptic... |
| 05.11.2020 | ObsEva Announces Third Quarter 2020 Financial Results and Bu... | Positive Phase 3 PRIMROSE 1 and 2 trial results of linzagolix for the treatment of heavy menstrual b... | marketscre... |
| 06.08.2020 | OBSEVA SA
ObsEva : Q2 Half Year Report 2020 | Half-Year Report 2020
Interim Condensed Consolidated IFRS
Financial Statements for the three-month a... | marketscre... |
| 07.11.2019 | ObsEva shares crater after PhIII fail; Allena Pharma u... | → Swiss biotech ObsEva SA — focused on treatments to improve women’s reproductive health — s... | endpts.com... |
| 08.08.2019 | ObsEva secures $75 million non-dilutive financing | | startuptic... |
| 07.08.2019 | ObsEva SA Announces $75 Million Credit Facility with Oxford ... | - | sofinnova.... |
| 19.07.2019 | Medicxi closes a €400M Fund to back biopharma entrepreneurs... | | startuptic... |
| 13.07.2018 | ObsEva with a positive start at Swiss Exchange | | startuptic... |
| 18.06.2018 | Seven biotech IPOs ready to roll; Celltrion's Herceptin ... | → Renaissance Capital is tracking 7 new biotech IPOs this week. The lineup includes Magenta... | endpts.com... |
| 01.03.2018 | ObsEva Reports Positive Phase 3 Results | | startuptic... |
| 10.10.2017 | ObsEva SA Announces $60.0 Million Private Placement with Exi... | Geneva, Switzerland and Boston, MA – 10 October, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage b... | aislingcap... |
| 02.03.2017 | Eclosion: Incubator for market stars in Geneva | | startuptic... |
| 05.02.2017 | The rise of femtech: women, technology, and Trump | Did you miss a session from GamesBeat Summit 2022? All sessions are available to stream now. Learn m... | venturebea... |
| 05.02.2017 | The rise of femtech: women, technology, and Trump | The market is flooded with products tailored to the needs of men: viagra, penis enlargement pills, f... | venturebea... |
| 18.01.2017 | ObsEva Expands Leadership Team as it prepares for IPO | | startuptic... |
| 18.01.2017 | Women’s health biotech ObsEva sets terms for $87M IPO | ObsEva has set the terms for an IPO that could net it in the region of $87 million (€81 million). Th... | fiercebiot... |
| 31.10.2016 | ObsEva announces IPO and Phase 3 clinical trials | | startuptic... |
| 04.08.2016 | ObsEva: Fifth compound in a clinical program | | startuptic... |
| 25.02.2016 | How to raise CHF100 million | | startuptic... |
| 24.11.2015 | ObsEva Closes CHF 60 Million in Series B Financing | | startuptic... |
| 23.11.2015 | Daily funding roundup - November 23, 2015 | ColorChip raised $25M; Quizlet secured $12M; Sportpursuit received $14.4M funding
South Korean apart... | vator.tv/n... |
| 23.11.2015 | ObsEva Closes US$60M Series B Financing | ObsEva, a Geneva, Switzerland-based biopharmaceutical company developing a novel generation of drugs... | finsmes.co... |
| 11.09.2015 | ObsEva presents encouraging results of the pharmacology stud... | | startuptic... |
| 03.03.2015 | ObsEva Reports Positive Phase 1 Results for Its Lead Compoun... | | startuptic... |
| 28.11.2014 | ObsEva Announces Initiation of a Pivotal Phase 2 Study | | startuptic... |
| 29.01.2014 | New Chairperson of the Board at ObsEva | | startuptic... |
| 29.08.2013 | ObsEva grabs $34.5M to launch out of Merck Serono rubble | Another biotech company is being assembled out of the wreckage left behind by Merck KGaA's restructu... | fiercebiot... |
| 29.08.2013 | ObsEva Raises EURO 25.6M in Series A |
GENEVA, SWITZERLAND, ObsEva today announced the closing of a CHF 32 million Series-A financing rou... | vcnewsdail... |
| 29.08.2013 | ObsEva Closes CHF32M Series A Financing | ObsEva, a Geneva, Switzerland-based biopharmaceutical company dedicated to the development of innova... | finsmes.co... |
| 29.08.2013 | ObsEva SA announces CHF 32 Million funding | | startuptic... |
| - | Stocks making the biggest moves midday: Abercrombie & Fi... | Check out the companies making headlines in midday trading.
Abercrombie & Fitch – Shares of the ... | cnbc.com/2... |